Serum interleukin-5 levels are elevated in mild and moderate persistent asthma irrespective of regular inhaled glucocorticoid therapy

BMC Pulmonary Medicine

Maries Joseph¹  Wassef Safa³  Sheela Benedict²  Jose Joseph² 

[1] Department of Pediatrics, Al Ain Hospital, Al Ain, UAE;Department of Internal Medicine, Faculty of Medicine and Health Sciences, Al Ain, UAE;Department of Internal Medicine, Tawam Hospital, Al Ain, UAE

关键词: inhaled steroids;    atopic asthma;    non-atopic asthma;    Interleukin-5;   

Others  :  1172942
DOI  :  10.1186/1471-2466-4-2

 received in 2003-11-01, accepted in 2004-03-17,  发布年份 2004

【 摘 要 】

Background

Interleukin-5 (IL-5) is thought to play a pivotal role in the pathogenesis of asthma. High levels of circulating IL-5 have been documented in acute asthma. However, serum IL-5 levels in mild to moderate asthmatics and the influence of regular use of inhaled glucocorticoids, is not known.

Methods

Fifty-six asthmatics and 56 age and sex matched controls were recruited prospectively from an outpatient department. Information on asthma severity and treatment was gathered by a questionnaire. Serum IL-5, total IgE and specific IgE levels were measured in a blinded fashion.

Results

There were 32 atopic and 24 non-atopic mild-to-moderate asthmatics. The median serum IL-5 levels in atopic asthmatics (9.5 pg/ml) and in non-atopic asthmatics (8.1 pg/ml) were significantly higher than in normal controls (4.4 pg/ml, both p < 0.003). However, median serum IL-5 levels in atopic and non-atopic asthmatics were not significantly different. The median serum IL-5 level was insignificantly higher in fourteen moderate persistent asthmatics (10.6 pg/ml) compared to forty-two mild persistent asthmatics (7.3 pg/ml) (p = 0.13). The median serum IL-5 levels in asthmatics using regular inhaled steroids (7.8 pg/ml) was not significantly different from those not using inhaled steroids (10.2 pg/ml). Furthermore, serum total IgE levels and eosinophil counts were not significantly different in those using versus those not using inhaled glucocorticoids.

Conclusion

Serum IL-5 levels are elevated in mild and moderate persistent atopic and non-atopic asthmatics. Regular use of inhaled glucocorticoids may not abrogate the systemic Th2 type of inflammatory response in mild-moderate persistent asthma.

【 授权许可】

   
2004 Joseph et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Ng Man Kwong G., Proctor A, Billings C, Duggan R, Das C, Whyte MK, Powell CV, Primhak R: Increasing prevalence of asthma diagnosis and symptoms in children is confined to mild symptoms. Thorax 2001, 56:312-314.
• [2]Ying S, Humbert M, Barkans J, Corrigan CJ, Pfister R, Menz G, Larche M, Robinson DS, Durham SR, Kay AB: Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J Immunol 1997, 158:3539-3544.
• [3]Hamelmann E, Gelfand EW: Role of IL-5 in the development of allergen-induced airway hyperresponsiveness. Int Arch Allergy Immunol 1999, 120:8-16.
• [4]Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR, Kay AB: Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992, 326:298-304.
• [5]Wang J, Palmer K, Lotvall J, Milan S, Lei XF, Matthaei KI, Gauldie J, Inman MD, Jordana M, Xing Z: Circulating, but not local lung, IL-5 is required for the development of antigen-induced airways eosinophilia. J Clin Invest 1998, 102:1132-1141.
• [6]Shiota Y, Arikita H, Horita N, Hiyama J, Ono T, Yamakido M: Intracellular IL-5 and T-lymphocyte subsets in atopic and nonatopic bronchial asthma. J Allergy Clin Immunol 2002, 109:294-298.
• [7]Wada K, Kaminuma O, Mori A, Nakata A, Ogawa K, Kikkawa H, Ikezawa K, Suko M, Okudaira H: IL-5-producing T cells that induce airway eosinophilia and hyperresponsiveness are suppressed by dexamethasone and cyclosporin A in mice. Int Arch Allergy Immunol 1998, 117 Suppl 1:24-27.
• [8]Sahid El-Radhi A, Hogg CL, Bungre JK, Bush A, Corrigan CJ: Effect of oral glucocorticoid treatment on serum inflammatory markers in acute asthma. Arch Dis Child 2000, 83:158-162.
• [9]Visser MJ, Postma DS, Brand PL, Arends LR, Duiverman EJ, Kauffman HF: Influence of different dosage schedules of inhaled fluticasone propionate on peripheral blood cytokine concentrations in childhood asthma. Clin Exp Allergy 2002, 32:1497-1503.
• [10]Kelly EA, Busse WW, Jarjour NN: Inhaled budesonide decreases airway inflammatory response to allergen. Am J Respir Crit Care Med 2000, 162:883-890.
• [11]National Heart Lung,and Blood Institute: Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Betheda, MD, National Institute of Health; 1997.
• [12]Virchow J.C.,Jr., Kroegel C, Walker C, Matthys H: Inflammatory determinants of asthma severity: mediator and cellular changes in bronchoalveolar lavage fluid of patients with severe asthma. J Allergy Clin Immunol 1996, 98:S27-S33.
• [13]Shi HZ, Xiao CQ, Zhong D, Qin SM, Liu Y, Liang GR, Xu H, Chen YQ, Long XM, Xie ZF: Effect of inhaled interleukin-5 on airway hyperreactivity and eosinophilia in asthmatics. Am J Respir Crit Care Med 1998, 157:204-209.
• [14]Hogan SP, Koskinen A, Foster PS: Interleukin-5 and eosinophils induce airway damage and bronchial hyperreactivity during allergic airway inflammation in BALB/c mice. Immunol Cell Biol 1997, 75:284-288.
• [15]Alexander AG, Barkans J, Moqbel R, Barnes NC, Kay AB, Corrigan CJ: Serum interleukin 5 concentrations in atopic and non-atopic patients with glucocorticoid-dependent chronic severe asthma. Thorax 1994, 49:1231-1233.
• [16]Hamelmann E, Cieslewicz G, Schwarze J, Ishizuka T, Joetham A, Heusser C, Gelfand EW: Anti-interleukin 5 but not anti-IgE prevents airway inflammation and airway hyperresponsiveness. Am J Respir Crit Care Med 1999, 160:934-941.
• [17]van Rensen EL, Stirling RG, Scheerens J, Staples K, Sterk PJ, Barnes PJ, Chung KF: Evidence for systemic rather than pulmonary effects of interleukin-5 administration in asthma. Thorax 2001, 56:935-940.
• [18]Hakonarson H, Maskeri N, Carter C, Grunstein MM: Regulation of TH1- and TH2-type cytokine expression and action in atopic asthmatic sensitized airway smooth muscle. J Clin Invest 1999, 103:1077-1087.
• [19]Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R, Hansel TT, Holgate ST, Sterk PJ, Barnes PJ: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000, 356:2144-2148.
• [20]Hauber HP, Gotfried M, Newman K, Danda R, Servi RJ, Christodoulopoulos P, Hamid Q: Effect of HFA-flunisolide on peripheral lung inflammation in asthma. J Allergy Clin Immunol 2003, 112:58-63.
• [21]Hertz M, Mahalingam S, Dalum I, Klysner S, Mattes J, Neisig A, Mouritsen S, Foster PS, Gautam A: Active vaccination against IL-5 bypasses immunological tolerance and ameliorates experimental asthma. J Immunol 2001, 167:3792-3799.
• [22]Kips JC, O'Connor BJ, Langley SJ, Woodcock A, Kerstjens HA, Postma DS, Danzig M, Cuss F, Pauwels RA: Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003, 167:1655-1659.
• [23]Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS: Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003, 167:199-204.
• [24]Kay AB, Menzies-Gow A: Eosinophils and interleukin-5: the debate continues. Am J Respir Crit Care Med 2003, 167:1586-1587.